A MORE PROMISTING FUTURE FOR PATIENTS

We have discovered treatments that have the therapeutic potential to transform the lives of patients with neurological disorders.

SCIENCE-BASED INNOVATION WITH BREAKTHROUGH OUTCOMES

Based on fundamental discoveries in the mechanisms of synaptic plasticity and neuronal cell death, we have identified potential treatments for Neurodegenerative Disorders that have eluded researchers for decades.

About NeurAegis

NeurAegis is a preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders.Founded in 2016, our initial focus is developing first-in-class novel protease inhibitors for mild traumatic brain injury (concussion) where there are currently no FDA approved treatments.

Proven Leadership

NeurAegis is lead by a team with deep, relevant experience for developing novel therapeutics.

Michel Baudry, PhD

Michel Baudry, PhD

Founder & CSO

David Baron, DO

David Baron, DO

Chief Medical Officer

Mike Palfreyman, DSc. PhD

Mike Palfreyman, DSc. PhD

SVP, Clinical Development